Dr. Vikram Khurana is a board-certified neurologist and neurobiologist. He holds an MD from the University of Sydney and a PhD in neurobiology from Harvard University, and he was trained in neurology and movement disorders at Brigham and Women’s and Massachusetts General Hospital. He currently directs a clinic at Brigham and Women’s Hospital that serves individuals with parkinsonism, ataxia and Multiple System Atrophy. Dr. Khurana’s laboratory within the Ann Romney Center and Harvard Stem Cell Institutes focuses on understanding and reversing alpha-synuclein misfolding in stem-cell models of Parkinson’s disease. Recently, he has integrated genetic and computational tools to identify proteome-scale cellular networks that directly impact alpha-synuclein toxicity and he recently contributed to work that led to the identification of stearoyl-coA desaturase as a druggable target in synucleinopathy, with a lead molecule now in Phase 1 clinical trials. Dr. Khurana has multiple lead/corresponding author papers in top-tier journals.